<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02831816</url>
  </required_header>
  <id_info>
    <org_study_id>ZX-ZP-0074 / 150316-103</org_study_id>
    <nct_id>NCT02831816</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Patient Preoperative Prep</brief_title>
  <official_title>Clinical Evaluation of ZP, A Patient Preoperative Skin Preparation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zurex Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zurex Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to demonstrate the antimicrobial efficacy of the ZP&#xD;
      Preoperative Prep on skin flora of the abdomen and inguinal regions of human subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 3, 2016</start_date>
  <completion_date type="Actual">August 3, 2017</completion_date>
  <primary_completion_date type="Actual">August 3, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial Reduction</measure>
    <time_frame>10 minutes post product application</time_frame>
    <description>A a 3-log per cm2 bacterial reduction on the inguinal region is considered a success.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial Reduction - Abdomen</measure>
    <time_frame>10 minutes post product application</time_frame>
    <description>A 2-log per cm2 bacterial reduction on the abdomen region is considered a success.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">640</enrollment>
  <condition>Surgical Skin Preparation</condition>
  <arm_group>
    <arm_group_label>ZP (70% IPA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isopropyl alcohol (IPA) 70%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ChloraPrep</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZP Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ZP without IPA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZuraPrep</intervention_name>
    <description>Apply topically.</description>
    <arm_group_label>ZP (70% IPA)</arm_group_label>
    <other_name>Isopropyl alcohol 70%</other_name>
    <other_name>ZP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ChloraPrep</intervention_name>
    <description>Apply topically.</description>
    <arm_group_label>ChloraPrep</arm_group_label>
    <other_name>CHG 2% / IPA 70%</other_name>
    <other_name>Chlorhexidine gluconate 2% / Isopropyl alcohol 70%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZP Vehicle</intervention_name>
    <description>Apply topically.</description>
    <arm_group_label>ZP Vehicle</arm_group_label>
    <other_name>ZP without IPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects of any race.&#xD;
&#xD;
          -  Subjects in good health.&#xD;
&#xD;
          -  Minimum skin flora baseline requirements on abdomen and groin.&#xD;
&#xD;
          -  Skin free of tattoos, dermatoses, abrasions, cuts, lesions, or other skin disorder&#xD;
             near or on the applicable test area.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Topical or systemic antimicrobial exposure within 14 days prior to screening and&#xD;
             treatment days, including antibiotics.&#xD;
&#xD;
          -  Subjects with a history of skin sensitivity, skin allergies, or skin cancer.&#xD;
&#xD;
          -  Subjects who are pregnant, attempting pregnancy, or nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BioScience Laboratories, Inc.</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <results_first_submitted>May 6, 2021</results_first_submitted>
  <results_first_submitted_qc>June 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2021</results_first_posted>
  <disposition_first_submitted>July 20, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>July 20, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 24, 2018</disposition_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02831816/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Enrollment consists of subjects that advanced from screening to randomization and treatment. Each subject had 2 test products applied bilaterally; therefore, the numbers will not add up uniformly across arms due to the pre-determined cohort/block design. Result totals will be less than than the treated number as the per subject/ area/intervention anatomical site must have an acceptable baseline count/flora.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>ZP (Isopropyl alcohol (IPA) 70%) or CP or ZP Vehicle&#xD;
Applied topically to ab (for 30 seconds) or groin (for 2 minutes).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="640"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ZP</title>
              <participants_list>
                <participants group_id="P1" count="589"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>CP</title>
              <participants_list>
                <participants group_id="P1" count="590"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vehicle</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="640"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treated Population</title>
          <description>Each subject could have received 2 out of 3 test products randomly assigned. Demographics were not stratified by test product due to study design. While 640 was the treated population, to be evaluable for efficacy, each subject anatomical sample site (4/per subject) would need to pass the minimum log10 cfu/cm^2 baseline requirements.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="640"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="18" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="581"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="576"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bacterial Reduction</title>
        <description>A a 3-log per cm2 bacterial reduction on the inguinal region is considered a success.</description>
        <time_frame>10 minutes post product application</time_frame>
        <population>Treated subjects with treatment day baseline criteria 5.0-7.5 log recoveries.</population>
        <group_list>
          <group group_id="O1">
            <title>Mean Log Reduction - ZP (70% IPA) - Groin</title>
            <description>Isopropyl alcohol (IPA) 70%&#xD;
ZuraPrep: Apply topically to groin.</description>
          </group>
          <group group_id="O2">
            <title>Mean Log Reduction - Groin - ChloraPrep</title>
            <description>Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%&#xD;
ChloraPrep: Apply topically to groin.</description>
          </group>
          <group group_id="O3">
            <title>Mean Log Reduction - Groin - ZP Vehicle</title>
            <description>ZP without IPA&#xD;
ZP Vehicle: Apply topically to the groin.</description>
          </group>
        </group_list>
        <measure>
          <title>Bacterial Reduction</title>
          <description>A a 3-log per cm2 bacterial reduction on the inguinal region is considered a success.</description>
          <population>Treated subjects with treatment day baseline criteria 5.0-7.5 log recoveries.</population>
          <units>log10 cfu/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="352"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" spread="1.33"/>
                    <measurement group_id="O2" value="4.01" spread="1.43"/>
                    <measurement group_id="O3" value="1.60" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Groin 10 minutes Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product cannot be more than 0.05 log10 cfu/cm2 less than the active control.</non_inferiority_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.221</ci_lower_limit>
            <ci_upper_limit>0.180</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Groin 10 minutes Average Treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>2.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.15</ci_lower_limit>
            <ci_upper_limit>2.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bacterial Reduction - Abdomen</title>
        <description>A 2-log per cm2 bacterial reduction on the abdomen region is considered a success.</description>
        <time_frame>10 minutes post product application</time_frame>
        <population>Treated subjects with treatment day baseline criteria 3.0-5.5 log10 recoveries.</population>
        <group_list>
          <group group_id="O1">
            <title>Mean Log Reduction - ZP (70% IPA) - Abdomen</title>
            <description>Isopropyl alcohol (IPA) 70%&#xD;
ZuraPrep: Apply topically to abdomen.</description>
          </group>
          <group group_id="O2">
            <title>Mean Log Reduction - Abdomen - ChloraPrep</title>
            <description>Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%&#xD;
ChloraPrep: Apply topically to Abdomen.</description>
          </group>
          <group group_id="O3">
            <title>Mean Log Reduction - Abdomen - ZP Vehicle</title>
            <description>ZP without IPA&#xD;
ZP Vehicle: Apply topically to the Abdomen.</description>
          </group>
        </group_list>
        <measure>
          <title>Bacterial Reduction - Abdomen</title>
          <description>A 2-log per cm2 bacterial reduction on the abdomen region is considered a success.</description>
          <population>Treated subjects with treatment day baseline criteria 3.0-5.5 log10 recoveries.</population>
          <units>log10 cfu/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="320"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" spread="1.1"/>
                    <measurement group_id="O2" value="2.79" spread="1.1"/>
                    <measurement group_id="O3" value="1.00" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Abdomen 10 minutes average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product cannot be more than 0.05 log10 cfu/cm2 less than the active control.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0435</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2085</ci_lower_limit>
            <ci_upper_limit>0.1215</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Abdomen 10 minutes Average Treatment Effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.70</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 hours post product application</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ZP (70% IPA)</title>
          <description>Isopropyl alcohol (IPA) 70%&#xD;
ZuraPrep: Apply topically.</description>
        </group>
        <group group_id="E2">
          <title>ChloraPrep</title>
          <description>Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%&#xD;
ChloraPrep: Apply topically.</description>
        </group>
        <group group_id="E3">
          <title>ZP Vehicle</title>
          <description>ZP without IPA&#xD;
ZP Vehicle: Apply topically.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="590"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="590"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="590"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Morgan</name_or_title>
      <organization>Zurex Pharma, Inc.</organization>
      <phone>16082039090</phone>
      <email>amorgan@zurexpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

